📰 Deric Dube News
Page 2 - Deric Dube News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Deric Dube. Real-time updates on events, politics, business and more.
November 7, 2023
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
October 12, 2023
/PRNewswire/ -- WHAT: Join the National Organization for Rare Disorders (NORD) Oct. 15-17, 2023 in Washington for the Rare Diseases and Orphan Products...
September 29, 2023
ONE of the countrys largest ferrochrome producers, Zimbabwe Alloys (ZimAlloys) will next month return to production after a new shareholder injected close to U...
September 21, 2023
Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head...
September 21, 2023
FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of...
August 8, 2023
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2023 Earnings Call Transcript August 4, 2023 Operator: Good day, and welcome to the Travere Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. Today’s conference call is being recorded. At this time, I would like to turn the conference call over to the Vice President of Investor […]
July 19, 2023
Mirum Pharmaceuticals gets two FDA-approved drugs targeting people with rare liver and kidney disorders
May 9, 2023
Operator: Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Todays conference is being recorded.
May 2, 2023
Sparsentan failed to meet the main goal of a Phase 3 test in focal segmental glomerulosclerosis (FSGS). Nevertheless, Travere Therapeutics says the totality of data points to patient improvement in the rare kidney disorder and the biotech will talk with regulators about a potential path forward.